Opiant Pharmaceuticals Inc Revenue Growth Rates (OPNT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Opiant Pharmaceuticals Inc   (NASDAQ: OPNT)
 

OPNT's Revenue Growth by Quarter and Year

Opiant Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OPNT Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 0.17
2nd Quarter June 3.89
1st Quarter March 4.47
FY 8.53

OPNTs Annual Revenue
Opiant Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 47.79 millions
Opiant Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 29.63 millions
Opiant Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 40.52 millions
Opiant Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 13.98 millions
Opiant Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 18.45 millions




OPNT Revenue third quarter 2022 Y/Y Growth Comment
Opiant Pharmaceuticals Inc reported drop in Revenue in the third quarter 2022 by -98.94% to $ 0.17 millions, from the same quarter in 2021.
The fall in the third quarter 2022 Opiant Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 1294.56%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 269 other companies have achieved higher Revenue growth. While Opiant Pharmaceuticals Inc ' s Revenue meltdown of -98.94% ranks overall at the positon no. 4044 in the third quarter 2022.


OPNT Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 39.11 % 29.34 % 61.13 %
3rd Quarter September -98.94 % 79.36 % -55.86 % 372.31 %
2nd Quarter June -65.45 % 78.45 % -6.93 % 115.24 %
1st Quarter March -30.05 % 49.3 % -21.32 % 220 %
FY   - 61.34 % -26.92 % -

Financial Statements
Opiant Pharmaceuticals Inc 's third quarter 2022 Revenue $ 0.17 millions OPNT's Income Statement
Opiant Pharmaceuticals Inc 's third quarter 2021 Revenue $ 16.34 millions Quarterly OPNT's Income Statement


OPNT Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - -15.54 % 8.89 % -62.84 %
3rd Quarter September -95.53 % 45.12 % 44.37 % 204.42 %
2nd Quarter June -12.98 % 76.21 % 47.43 % 24.63 %
1st Quarter March -67.61 % -35.58 % -44.2 % 14.29 %
FY (Year on Year)   - 61.34 % -26.92 % -


Back to OPNT Growth rate Comparisons >> Back to OPNT Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #270
Healthcare Sector #668
Overall #4044

Revenue Y/Y Growth Statistics
High Average Low
19745.45 % 1294.56 % -99.3 %
(Sep 30 2018)   (Apr 30 2017)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #270
Healthcare Sector #668
Overall #4044
Revenue Y/Y Growth Statistics
High Average Low
19745.45 % 1294.56 % -99.3 %
(Sep 30 2018)   (Apr 30 2017)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Opiant Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
22040.36 % 1720.07 % -99.87 %
(Dec 31 2017)  


OPNT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Opiant Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -95.53% to $ 0.17 millions, from $ 3.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 273 other companies have achieved higher Revenue quarter on quarter growth. While Opiant Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4048.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #274
Healthcare Sector #708
Overall #4048
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #274
Healthcare Sector #708
Overall #4048
Revenue Q/Q Growth Statistics
High Average Low
22040.36 % 1720.07 % -99.87 %
(Dec 31 2017)  


OPNT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Opiant Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -95.53% to $ 0.17 millions, from $ 3.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 273 other companies have achieved higher Revenue quarter on quarter growth. While Opiant Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4048.


Opiant Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 22.34 $ 38.50 $ 45.87 $ 47.79 $ 43.91
Y / Y Revenue Growth (TTM) -49.13 % 4.98 % 44.56 % 61.3 % 60.43 %
Year on Year Revenue Growth Overall Ranking # 567 # 2225 # 726 # 356 # 337
Seqeuential Revenue Change (TTM) -41.98 % -16.06 % -4.01 % 8.83 % 19.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 1374 # 3425 # 2999 # 740 # 414


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2022 Opiant Pharmaceuticals Inc reported a sharp drop in Revenue by -49.13% year on year, to $22 millions, compare to the 4.98% growth at Jun 30 2022.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 567, from total ranking in previous quarter at 2225.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 114
Overall # 567

Revenue TTM Y/Y Growth Statistics
High Average Low
1447.25 %
 111.75 %
-49.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 216
S&P 500 # 1374
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2022 Opiant Pharmaceuticals Inc reported a sharp drop in Revenue by -49.13% year on year, to $22 millions, compare to the 4.98% growth at Jun 30 2022.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 567, from total ranking in previous quarter at 2225.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 114
Overall # 567

Revenue TTM Y/Y Growth Statistics
High Average Low
1447.25 %
111.75 %
-49.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 216
S&P 500 # 1374




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OPNT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Nrc Health-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc-0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Bausch and Lomb Corp-0.74%$ -0.738 millions
Amgen Inc -0.81%$ -0.805 millions
Syneos Health Inc -0.89%$ -0.891 millions
Hologic Inc-0.93%$ -0.925 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Regen Biopharma Inc -1.09%$ -1.088 millions
Procyon Corporation-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Fresenius Medical Care Ag-1.99%$ -1.990 millions
Hca Healthcare Inc -2.00%$ -1.997 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions


About Opiant Pharmaceuticals Inc Revenue Growth Rates (OPNT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Opiant Pharmaceuticals Inc (CIK 1385508).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001385508-22-000131
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Opiant Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.